These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 10466753)
21. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. Zheleva DI; Lane DP; Fischer PM Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949 [TBL] [Abstract][Full Text] [Related]
22. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics]. Marine Ch Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148 [TBL] [Abstract][Full Text] [Related]
23. [The importance of a SNiP of the MDM2 gene to modulate the p53 pathway and the predisposition to cancer]. Larsen CJ Bull Cancer; 2011 Jan; 98(1):10. PubMed ID: 21591298 [No Abstract] [Full Text] [Related]
24. p53-Mdm2--the affair that never ends. Alarcon-Vargas D; Ronai Z Carcinogenesis; 2002 Apr; 23(4):541-7. PubMed ID: 11960904 [TBL] [Abstract][Full Text] [Related]
25. An insight into the life of p53: a protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998. Almog N; Rotter V Biochim Biophys Acta; 1998 Nov; 1378(3):R43-54. PubMed ID: 9875245 [No Abstract] [Full Text] [Related]
26. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934 [TBL] [Abstract][Full Text] [Related]
27. Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy. Lane D Carcinogenesis; 2004 Jul; 25(7):1077-81. PubMed ID: 15205365 [TBL] [Abstract][Full Text] [Related]
28. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Montes de Oca Luna R; Wagner DS; Lozano G Nature; 1995 Nov; 378(6553):203-6. PubMed ID: 7477326 [TBL] [Abstract][Full Text] [Related]
30. The p53 and Mdm2 families in cancer. Michael D; Oren M Curr Opin Genet Dev; 2002 Feb; 12(1):53-9. PubMed ID: 11790555 [TBL] [Abstract][Full Text] [Related]
31. The p53 mutation "gradient effect" and its clinical implications. Zambetti GP J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971 [TBL] [Abstract][Full Text] [Related]
32. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. Unger T; Juven-Gershon T; Moallem E; Berger M; Vogt Sionov R; Lozano G; Oren M; Haupt Y EMBO J; 1999 Apr; 18(7):1805-14. PubMed ID: 10202144 [TBL] [Abstract][Full Text] [Related]
33. [Progress of p53 gene]. Xu SF; Fu L Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):559-61. PubMed ID: 15634457 [No Abstract] [Full Text] [Related]
35. MDM2 is a central node in the p53 pathway: 12 years and counting. Bond GL; Hu W; Levine AJ Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184 [TBL] [Abstract][Full Text] [Related]
37. Drug discovery and p53. Lane DP; Hupp TR Drug Discov Today; 2003 Apr; 8(8):347-55. PubMed ID: 12681938 [TBL] [Abstract][Full Text] [Related]
38. Tumors in tadpoles: the Xenopus embryo as a model system for the study of tumorigenesis. Wallingford JB Trends Genet; 1999 Oct; 15(10):385-8. PubMed ID: 10498932 [No Abstract] [Full Text] [Related]
39. Oncology. Recruiting the cell's own guardian for cancer therapy. Marx J Science; 2007 Mar; 315(5816):1211-3. PubMed ID: 17332387 [No Abstract] [Full Text] [Related]